| 1 |
NCT03608202 |
Recruiting |
Impact of a Multisystemic Ultrasound Protocol in Patients of Polyvalent Intensive Care Units |
|
- Behavioral: POCUS protocol group
- Other: Control group
|
Interventional
|
Not Applicable |
- Asociacion Española Primera en Salud
- Intensive Care Unit Pasteur Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Changes in diagnosis and treatment by point of care ultrasound
- Definitive diagnosis
- ICU extra requirements
- (and 5 more...)
|
126 |
All |
18 Years and older (Adult, Older Adult) |
NCT03608202 |
AsociacionEPS |
|
November 2016 |
July 2018 |
December 2018 |
July 31, 2018 |
July 31, 2018 |
|
- UCI Hospital Pasteur y Asociacion Española
Montevideo, Uruguay
|
|
| 2 |
NCT03202030 |
Recruiting |
Immediate Dentoalveolar Restoration Compared to Bio-oss |
- Fresh Sockets With Buccal Resorption
|
- Procedure: Immediate dentoalveolar restoration
- Procedure: Demineralized bovine bone
|
Interventional
|
Not Applicable |
- Federal University of Rio Grande do Sul
- University of the Republic, Uruguay
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Investigator)
- Primary Purpose: Treatment
|
- Buccal-palatal thickness
- Oral-health related quality of life
|
34 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03202030 |
Udelar |
IDRBio-oss |
January 2016 |
January 2018 |
January 2020 |
June 28, 2017 |
June 28, 2017 |
|
- Universidad de La Republica del Uruguay
Montevideo, Uruguay
|
|
| 3 |
NCT03180424 |
Enrolling by invitation |
Impact on Functional Status in Older Adults Treated With L-Carnitine |
- Carnitine; Muscle
- Functional Status
- Old Age; Debility
|
- Drug: L Carnitine
- Behavioral: Supervised exercise
- Drug: Placebos
- Behavioral: Exercise at home
|
Interventional
|
Phase 2
Phase 3 |
- Hospital de Clínicas Dr. Manuel Quintela
- University of the Republic, Uruguay
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Changes in elderly's function
- Gait speed
- Elderly's physical performance
- Changes in the expression of fragility criteria
|
60 |
All |
65 Years and older (Older Adult) |
NCT03180424 |
Protocolo L-Carnitina |
|
January 1, 2017 |
August 31, 2017 |
September 30, 2017 |
June 8, 2017 |
June 8, 2017 |
|
- Hospital de Clinicas Dr. Manuel Quintela
Montevideo, Uruguay
|
|
| 4 |
NCT02189538 |
Unknown † |
Effect of n-3 PUFA From Fish in Enteral Nutrition of Major Burn Patients |
|
- Dietary Supplement: ω-3 PUFA
- Dietary Supplement: Low fat enteral diet
|
Interventional
|
Not Applicable |
- Centro Nacional de Quemados, Uruguay
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Supportive Care
|
- Number of infections
- Non infectious complications
|
100 |
All |
16 Years to 80 Years (Child, Adult, Older Adult) |
NCT02189538 |
Universidad de la República |
OmegaBurn |
January 2013 |
December 2017 |
February 2018 |
July 14, 2014 |
February 15, 2017 |
|
- Centro National de Quemados
Montevideo, Uruguay
|
|
| 5 |
NCT02132897 |
Completed |
Fed Bioequivalence Study of CBZ Formulations |
- Bio-equivalence Study
- Fed Conditions
|
- Drug: Auration CR Tablets 400 Single Dose-Tegretol CR 400 Single Dose
- Drug: Tegretol CR 400 Single Dose-Auration CR 400 Single Dose
|
Interventional
|
Phase 1 |
- Center for Clinical Pharmacology Research Bdbeq S.A.
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Single (Investigator)
|
|
20 |
Male |
18 Years to 50 Years (Adult) |
NCT02132897 |
BDBEQ-CBZ400/EUFUY-023 |
|
May 2014 |
June 2014 |
June 2014 |
May 7, 2014 |
June 17, 2014 |
|
- Center for Clinical Pharmacology Research Bdbeq S.A. Italian Hospital
Montevideo, Uruguay
|
|
| 6 |
NCT01760356 |
Active, not recruiting |
Study of PD/PK/PG Relationships of Tacrolimus and Cyclosporin in Liver Transplant Patients |
- End Stage Liver Disease
- Rejection
- Infection
- (and 3 more...)
|
|
Observational
|
|
- UDA Centro Nacional Hepato-Bilio-Pancreático
- INSERM UMR-S850, Limoges, France
- University Hospital, Limoges
- (and 7 more...)
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Change in Percentage of expression of CD25High in CD3, CD4 and CD8 T Lymphocytes.
- Pharmacogenetic investigations
- Anticalcineurin drug concentration through levels
- (and 11 more...)
|
141 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT01760356 |
3PIGREF- 2009 -1165 |
3PIGREF |
May 2011 |
February 2015 |
December 2018 |
January 4, 2013 |
October 27, 2017 |
|
- National Center for Liver Transplantation and Liver Diseases Department, Hospital Central de las Fuerzas Armadas
Montevideo, Uruguay
|
|
| 7 |
NCT01750749 |
Completed |
Cell Therapy for Venous Leg Ulcers Pilot Study |
|
- Biological: Autologous BMDC implantation at the venous ulcer
|
Interventional
|
Phase 1 |
- Hospital de Clínicas Dr. Manuel Quintela
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Reduction of the ulcer area at 2 months
- Reduction of the ulcer area at 4 months
- Reduction of the ulcer area at 6 months
- (and 4 more...)
|
4 |
All |
40 Years to 75 Years (Adult, Older Adult) |
NCT01750749 |
TUV2011 |
|
May 2011 |
December 2013 |
June 2014 |
December 17, 2012 |
March 6, 2017 |
|
- Universidad de la República- Hospital de Clínicas Dr. Manuel Quintela
Montevideo, Uruguay
|
|
| 8 |
NCT01704898 |
Completed |
Efavirenz Comparative Bioavailability |
|
- Drug: Efavirenz 600 Test-Stocrin 600 Reference
- Drug: Stocrin 600 Reference-Efavirenz 600 Test
|
Interventional
|
Phase 4 |
- Center for Clinical Pharmacology Research Bdbeq S.A.
- University of the Republic, Uruguay
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Single (Investigator)
- Primary Purpose: Treatment
|
- Area Under the Curve for efavirenz (AUC0-192)
- Maximum Concentration for efavirenz (Cmax)
- Area Under the Curve 0 to infinity for efavirenz (AUC0-inf)
- Time to the Cmax for efavirenz (tmax)
|
12 |
Male |
18 Years to 50 Years (Adult) |
NCT01704898 |
bdbeq-efv600/icuvita-020 |
efv600 |
April 2013 |
June 2013 |
August 2013 |
October 12, 2012 |
August 14, 2013 |
|
- Center for Cllinical Pharmacology Research-Bdbeq S.A.
Montevideo, Uruguay
|
|
| 9 |
NCT01229280 |
Unknown † |
Single Dose Bioequivalence Study of Darifenacin Tablets 7.5 mg in Fed Healthy Volunteers. |
|
|
Interventional
|
Phase 1 |
- Center for Clinical Pharmacology Research Bdbeq S.A.
- Laboratorio Elea S.A.C.I.F. y A.
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
|
- Extent of absorption
- Rate of absorption
- Time to peak concentration (tmax)
- (and 3 more...)
|
24 |
All |
18 Years to 50 Years (Adult) |
NCT01229280 |
BDBEQ_DFNLP/ELEA_010 |
|
December 2010 |
January 2011 |
February 2011 |
October 27, 2010 |
October 27, 2010 |
|
- Center for Clinical Pharmacology Research (CCPR) Bdbeq S.A. Hospital Italiano.
Montevideo, Uruguay
|
|
| 10 |
NCT01227811 |
Unknown † |
Single Dose Two-periods Crossover Bioequivalence Study of Darifenacin Tablets in Healthy Volunteers. |
|
|
Interventional
|
Phase 1 |
- Center for Clinical Pharmacology Research Bdbeq S.A.
- Laboratorio Elea S.A.C.I.F. y A.
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
|
- Extent of Absorption.
- Rate of Absorption
- Time to peak concentration (tmax)
- (and 2 more...)
|
24 |
All |
18 Years to 50 Years (Adult) |
NCT01227811 |
BDBEQ_DFNLP/ELEA_011 |
|
November 2010 |
December 2010 |
March 2011 |
October 25, 2010 |
October 25, 2010 |
|
- Center for Clinical Pharmacology Research Bdbeq S.A.; Hospital Italiano de Montevideo..
Montevideo, Uruguay
|
|
| 11 |
NCT00873314 |
Completed |
Bed Rest for Threatened Preterm Labor. Pilot Study |
|
- Behavioral: Bed rest
- Behavioral: Activity restriction
|
Interventional
|
Not Applicable |
- Institute for Clinical Effectiveness and Health Policy
- Unidad de Investigación Clínica y Epidemiológica Montevideo
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- The outcome was the amount of activity. In order to measure the outcome, we used: a) an accelerometer which was delivered to the woman at home and b) a diary record that the woman fulfilled during the study.
|
46 |
Female |
Child, Adult, Older Adult |
NCT00873314 |
CIHR01-2003 |
|
July 2006 |
November 2006 |
November 2006 |
April 1, 2009 |
April 1, 2009 |
|
- Pereira Rossell Hospital
Montevideo, Uruguay
|
|
| 12 |
NCT00561106 |
Completed |
Prednisone-Placebo vs Prednisone-Valacyclovir in Bell´s Palsy |
|
- Drug: prednisone- valacyclovir
- Drug: prednisone-placebo
|
Interventional
|
Not Applicable |
- Universidad de la Republica
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- The following parameters were used to evaluate the final result: grade of recovery, and sequelae.Facial nerve function was assessed using the facial grading system (FGS) Normal recovery was defined as the return of facial function to FGS 90 or more.
|
42 |
All |
14 Years to 82 Years (Child, Adult, Older Adult) |
NCT00561106 |
HC 6-8-02 |
PVBP |
December 2002 |
|
December 2003 |
November 20, 2007 |
November 20, 2007 |
|
- Hospital de clinicas
Montevideo, Uruguay
|
|
| 13 |
NCT00374790 |
Completed |
Iron Supplementation of Lead-exposed Infants |
|
|
Interventional
|
Phase 2 |
- Cornell University
- Thrasher Research Fund
|
Other |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: Double
- Primary Purpose: Prevention
|
- Incidence of blood lead concentrations > 10 mcg/dL
- Mean hemoglobin concentration
- Mean zinc protoporphyrin concentration
- (and 2 more...)
|
50 |
All |
6 Months to 18 Months (Child) |
NCT00374790 |
0604015 |
|
October 2006 |
May 2008 |
July 2008 |
September 11, 2006 |
May 15, 2018 |
|
- Clinic for Environmnetal Contaminants
Montevideo, Uruguay
|
|
| 14 |
NCT00070720 |
Completed |
Improving Perinatal Care in Latin America |
|
- Behavioral: Opinion Leaders, Academic Detailing, Reminders, and Feedback
|
Interventional
|
Phase 4 |
- NICHD Global Network for Women's and Children's Health
- Global Network for Women's and Children's Health Research
- Bill and Melinda Gates Foundation
- (and 10 more...)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
|
- Episiotomies
- Oxytocin use in third stage of labor
- Perineal sutures
- (and 2 more...)
|
21780 |
All |
Child, Adult, Older Adult |
NCT00070720 |
GN 01
U01HD040477 |
|
September 2003 |
|
December 2006 |
October 13, 2003 |
December 17, 2013 |
|
- Hospital de Clinicas
Montevideo, Uruguay
|
|
| 15 |
NCT00781066 |
Completed |
Controlled Cord Traction During Third Stage of Labor |
|
- Procedure: Controlled cord traction
- Procedure: No controlled cord traction
|
Interventional
|
Phase 3 |
- Universidad de la Republica
- Unidad de Investigación Clínica y Epidemiológica Montevideo
- Institute for Clinical Effectiveness and Health Policy
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Postpartum blood loss
- Manual removal of placenta
- Uterine inversion
- (and 3 more...)
|
200 |
Female |
18 Years and older (Adult, Older Adult) |
NCT00781066 |
CCT 06-00051
D43TW005492 (NIH grant number)
D43TW005492 |
CCT |
January 2007 |
September 2007 |
September 2007 |
October 28, 2008 |
October 28, 2008 |
|
- Clinica's Hospital Manuel Quintela of the University of the Republic of Uruguay
Montevideo, Uruguay - Pereira Rossell Hospital
Montevideo, Uruguay
|
|
| 16 |
NCT02600624 |
Recruiting |
Prenatal Alcohol Biomarker Study in Uruguay |
|
|
Observational
|
|
|
Other |
- Observational Model: Case-Only
- Time Perspective: Cross-Sectional
|
- Newborn Phosphatidylethanol Screening to Detect Fetal Alcohol Exposure in Uruguay
|
1800 |
Female |
18 Years and older (Adult, Older Adult) |
NCT02600624 |
STU00200504 |
|
August 18, 2016 |
July 2019 |
July 2019 |
November 9, 2015 |
August 22, 2018 |
|
- Northwestern Memorial Hospital
Chicago, Illinois, United States - Clínica Ginecología/Obstétrica del Hospital General de las Fuerzas Armadas de Uruguay
Montevideo, Uruguay
|
|
| 17 |
NCT02535026 |
Completed
Has Results |
An Observational Study on Human Epidermal Growth Factor Receptor (HER) 2 Status of Breast Invasive Carcinoma in Latin American Participants |
|
|
Observational
|
|
|
Industry |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Percentage of Participants With Human Epidermal Growth Factor Receptor 2 (HER2) Status in Breast Cancer Specimens Using Immunohistochemistry (IHC) and Silver In-Situ Hybridization (SISH) Procedures
- Percentage of Participants With Different Phenotypes of Breast Cancer
- Percentage of Participants With Histological Sub-types of Breast Cancer
- (and 16 more...)
|
580 |
Female |
18 Years and older (Adult, Older Adult) |
NCT02535026 |
ML25371 |
|
July 2011 |
December 2013 |
December 2013 |
August 28, 2015 |
April 10, 2017 |
April 10, 2017 |
- Lima, Peru
- Lima, Peru
- Lima, Peru
- Montevideo, Uruguay
|
|
| 18 |
NCT01852617 |
Completed |
A Smoking Cessation Intervention During Pregnancy in Argentina and Uruguay |
- Smoking Cessation
- Pregnancy
|
- Behavioral: Training in smoking cessation counseling
|
Interventional
|
Not Applicable |
- Institute for Clinical Effectiveness and Health Policy
- Tulane University
- Centers for Disease Control and Prevention
|
Other / U.S. Fed |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Health Services Research
|
- Frequency of women receiving the cessation smoking advice
- Frequency of women who smoke at the end of pregnancy
- Frequency of providers' positives attitudes and readiness to change
|
6858 |
Female |
12 Years to 49 Years (Child, Adult) |
NCT01852617 |
1U48DP001948-01 |
|
October 2011 |
November 2013 |
August 2014 |
May 14, 2013 |
January 30, 2015 |
|
- Hospital Bocalandro
Tres de Febrero, Buenos Aires Province, Argentina - Hospital Lucio Meléndez
Adrogué, Buenos Aires, Argentina - Hospital Evita Pueblo
Berazategui, Buenos Aires, Argentina - (and 19 more...)
|
|
| 19 |
NCT02730052 |
Not yet recruiting |
Telemonitoring of Uncontrolled Hypertension |
|
- Device: Omron 9200T plus Telemonitoring
- Device: Omron 9200T without Telemonitoring
|
Interventional
|
Phase 4 |
- Universidad de la Republica
- Hospital Italiano de Buenos Aires
- KU Leuven
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Time to blood pressure control
- The proportion of patients reaching blood pressure control on self-measurement at home and office measurement
- The proportion of patients reaching and maintaining blood pressure control on self-measurement and office measurement at the late follow-up visit
- (and 6 more...)
|
300 |
All |
20 Years to 79 Years (Adult, Older Adult) |
NCT02730052 |
11/16 |
ERNESTINA |
June 2016 |
June 2019 |
December 2019 |
April 6, 2016 |
April 6, 2016 |
|
- Center AR-4
Ciudad de Cordoba, Cordoba, Argentina - Center AR-3
Rosario, Santa-Fe, Argentina - Center AR-1
Buenos Aires, Argentina - (and 5 more...)
|
|
| 20 |
NCT01093482 |
Completed
Has Results |
Third International Study on Mechanical Ventilation |
- Acute Respiratory Failure
|
|
Observational
|
|
- Hospital Universitario Getafe
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
|
8151 |
All |
18 Years and older (Adult, Older Adult) |
NCT01093482 |
ISMV-2010 |
ISMV |
April 2010 |
July 2010 |
September 2010 |
March 25, 2010 |
March 1, 2018 |
January 26, 2018 |
- University of Iowa Hospitals and Clinics
Iowa City, Iowa, United States - University of Louisville School of Medicine
Louisville, Kentucky, United States - Boston Medical Center
Boston, Massachusetts, United States - (and 474 more...)
|
|
| 21 |
NCT01970189 |
Recruiting |
The International ITP Registry |
|
|
Observational
|
|
- South Eastern Sydney Local Health District
- GlaxoSmithKline
|
Other / Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Disease progression of ITP
|
500 |
All |
18 Years and older (Adult, Older Adult) |
NCT01970189 |
CTBR-017 (TRA114972) |
|
January 2011 |
December 2016 |
December 2020 |
October 28, 2013 |
October 27, 2016 |
|
- Canberra Hospital
Canberra, Australian Capital Territory, Australia - St George Hospital
Sydney, New South Wales, Australia - Calvary Mater Newcastle
Sydney, New South Wales, Australia - (and 41 more...)
|
|
| 22 |
NCT01572038 |
Active, not recruiting |
A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer |
|
- Drug: Docetaxel
- Drug: Nab-paclitaxel
- Drug: Paclitaxel
- (and 2 more...)
|
Interventional
|
Phase 3 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percentage of Participants With AEs Leading to Study Treatment Interruption and Discontinuation
- Percentage of Participants who Died, Reported by Cause of Death
- Percentage of Participants with Congestive Heart Failure (CHF)
- (and 10 more...)
|
1436 |
All |
18 Years and older (Adult, Older Adult) |
NCT01572038 |
MO28047
2011-005334-20 |
PERUSE |
June 1, 2012 |
September 28, 2019 |
September 28, 2019 |
April 5, 2012 |
October 10, 2018 |
|
- CPMC; Service d'Oncologie Médicale
Algiers, Algeria - Centro Oncologico Riojano Integral (CORI)
La Rioja, Argentina - Instituto de Oncología de Rosario
Rosario, Argentina - (and 322 more...)
|
|
| 23 |
NCT01566721 |
Active, not recruiting
Has Results |
A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer |
|
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percentage of Participants With At Least 1 Adverse Event (AE) During the Treatment Period
- Percentage of Participants With a Grade 3 or Higher AE During the Treatment Period
- Percentage of Participants With Treatment Interruption Due to an AE
- (and 8 more...)
|
2577 |
All |
18 Years and older (Adult, Older Adult) |
NCT01566721 |
MO28048
2011-005328-17 |
SafeHER |
May 17, 2012 |
March 10, 2015 |
March 3, 2020 |
March 29, 2012 |
September 12, 2018 |
April 18, 2017 |
- University "Mother Theresa" Hospital Center; Oncology Department
Tirana, Albania - CPMC; Service d'Oncologie Médicale
Algiers, Algeria - Fundación CENIT para la Investigación en Neurociencias
Buenos Aires, Argentina - (and 480 more...)
|
|
| 24 |
NCT00141193 |
Completed |
Prevention of Colorectal Sporadic Adenomatous Polyps (PRESAP) |
|
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- To evaluate the effects of celecoxib in reducing the proportion of subjects with new colorectal adenomas post baseline polypectomy after Month 13 (Year 1) and Month 37 (Year 3) of study drug administration.
- The number of colorectal adenomas in study subjects
- the histopathologic grade of colorectal adenomas
- the size of colorectal adenomas measured after one year and three years of study drug use.
|
1561 |
All |
30 Years and older (Adult, Older Adult) |
NCT00141193 |
EQ4-00-02-018
A3191107 |
PRESAP |
February 2001 |
May 2007 |
May 2007 |
September 1, 2005 |
August 6, 2008 |
|
- Pfizer Investigational Site
San Diego, California, United States - Pfizer Investigational Site
San Kiego, California, United States - Pfizer Investigational Site
North Chicago, Illinois, United States - (and 103 more...)
|
|
| 25 |
NCT02326857 |
Active, not recruiting |
Molecular Profiling of Stage II and III Breast Cancer in Latin American Women Receiving Standard-of-Care Treatment |
|
|
Observational
|
|
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Characterize distribution of invasive breast cancer stage II and III molecular profiles
- Association of molecular profile with tumor histological type, size,lymph node status and surrogate markers
- Proportion of participants in each molecular profile who achieve pCR to neoadjuvant chemotherpay
- (and 4 more...)
|
1334 |
Female |
18 Years to 100 Years (Adult, Older Adult) |
NCT02326857 |
999915055
15-C-N055 |
|
December 23, 2014 |
December 23, 2014 |
December 31, 2018 |
December 30, 2014 |
November 9, 2018 |
|
- Instituto Leloir
Buenos Aires, Argentina - Instituto Nacional de Cancer (INCA)
Rio de Janeiro, Brazil - Instituto do C(SqrRoot) ncer do Estado de S(SqrRoot) o Paulo
Sao Paulo, Brazil - (and 6 more...)
|
|
| 26 |
NCT01602419 |
Completed |
Surveillance of Safety and Efficacy of Wilate in Patients With Von Willebrand Disease |
|
- Other: Patients using wilate as standard of care
|
Observational
|
|
|
Industry |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Safety and tolerability
- Efficacy
|
120 |
All |
Child, Adult, Older Adult |
NCT01602419 |
Wil-20 |
|
October 2012 |
December 2017 |
December 2017 |
May 21, 2012 |
January 29, 2018 |
|
- Octapharma Research Site
Torrance, California, United States - Octapharma Research Site
Miami, Florida, United States - Octapharma Research Site
Salt Lake City, Utah, United States - (and 21 more...)
|
|
| 27 |
NCT01543503 |
Completed
Has Results |
An Global Comparative Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis |
|
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Mean Change From Baseline in Calculated Disease Activity Score Based on 28 Joint Count Erythrocyte Sedimentation Rate at Week 24
- Mean Change From Baseline in Disease Activity Score Based on 28 Joint Count Erythrocyte Sedimentation Rate at Week 52
- Mean Change From Baseline in Erythrocyte Sedimentation Rate
- (and 17 more...)
|
1225 |
All |
18 Years and older (Adult, Older Adult) |
NCT01543503 |
MA27950 |
|
February 2012 |
February 2015 |
February 2015 |
March 5, 2012 |
February 10, 2016 |
February 10, 2016 |
- Catamarca Capital, Argentina
- Mendoza, Argentina
- Mendoza, Argentina
- (and 151 more...)
|
|
| 28 |
NCT00517413 |
Completed
Has Results |
LATINO Study: A Study of Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia. |
|
- Drug: methoxy polyethylene glycol-epoetin beta [Mircera]
|
Interventional
|
Phase 3 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percentage of Participants Maintaining Their Mean Hb Concentration Within ±1.0 Gram/Deciliter of Their Reference Hb and Between 10.5 and 12.5 Gram/Deciliter
- Mean Change in the Hb Concentration Between the Stability Verification Period and the EEP
- Percentage of Participants Maintaining Hb Concentration Within The Target Range 10.5 and 12.5 g/dL Throughout the EEP
- (and 15 more...)
|
163 |
All |
18 Years and older (Adult, Older Adult) |
NCT00517413 |
ML20881 |
|
October 2007 |
May 2010 |
May 2010 |
August 17, 2007 |
April 29, 2016 |
April 29, 2016 |
- Buenos Aires, Argentina
- Buenos Aires, Argentina
- Buenos Aires, Argentina
- (and 25 more...)
|
|
| 29 |
NCT00391092 |
Completed
Has Results |
A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer. |
|
- Drug: bevacizumab [Avastin]
- Drug: Docetaxel
- Drug: Herceptin
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression Free Survival (PFS)
- Overall Survival (OS)
- Percentage of Participants With a Best Overall Response (OR) of Confirmed Complete Response (CR) or Partial Response (PR) in Participants With Measurable Disease at Baseline
- (and 4 more...)
|
424 |
All |
18 Years and older (Adult, Older Adult) |
NCT00391092 |
BO20231 |
|
September 2006 |
August 2014 |
August 2014 |
October 23, 2006 |
August 28, 2015 |
August 14, 2015 |
- Buenos Aires, Argentina
- Cordoba, Argentina
- La Plata, Argentina
- (and 87 more...)
|
|
| 30 |
NCT00088530 |
Completed
Has Results |
BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL) |
|
- Drug: pixantrone, cyclophosphamide, vincristine, rituximab, prednisone
- Drug: Vinorelbine, Oxalplatin, Ifosfasmide, Etoposide, Mitoxatrone, Gemcitabine or Rituximab
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Complete Response (CR) and Complete Response Unconfirmed (CRu)
- Progression-Free Survival (PFS)
- Overall Survival
- Overall Response Rate (ORR) Lasting at Least 4 Months
|
140 |
All |
18 Years and older (Adult, Older Adult) |
NCT00088530 |
PIX301 |
|
July 2004 |
February 2010 |
July 2010 |
July 29, 2004 |
November 8, 2018 |
June 1, 2017 |
- Robert A. Moss, M.D., FACP, Inc.
Fountain Valley, California, United States - UCLA Medical Center
Los Angeles, California, United States - Watson Clinic for Cancer Care and Research
Lakeland, Florida, United States - (and 96 more...)
|
|
| 31 |
NCT02789540 |
Completed |
Latin American Study of 24-hs Symptoms in Chronic Obstructive Pulmonary Disease (COPD) Patients; LASSYC Study |
|
|
Observational
|
|
|
Industry |
- Observational Model: Case-Only
- Time Perspective: Cross-Sectional
|
- Prevalence and severity of daily COPD symptoms
- Prevalence and severity of early morning COPD symptoms
- Prevalence and severity of night-time COPD symptoms
|
900 |
All |
Child, Adult, Older Adult |
NCT02789540 |
D2287R00112 |
LASSYC |
June 10, 2016 |
October 31, 2016 |
October 31, 2016 |
June 3, 2016 |
November 7, 2017 |
|
- Research Site
Buenos Aires, Argentina - Research Site
Santiago, Chile - Research Site
Bogota, Colombia - (and 3 more...)
|
|
| 32 |
NCT03721289 |
Not yet recruiting
New |
Evaluation in Real World of Molecular Testing and Treatment Patterns for EGFR Mutation in Lung Cancer Patients |
- Carcinoma, Non-Small-Cell Lung
|
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Retrospective
|
- Evaluation of the EGFR mutation
|
615 |
All |
18 Years to 99 Years (Adult, Older Adult) |
NCT03721289 |
D133FR00143 |
PANORAMRETRO |
November 19, 2018 |
May 31, 2019 |
May 31, 2019 |
October 26, 2018 |
November 5, 2018 |
|
- Research Site
Caba, Argentina - Research Site
Córdoba, Argentina - Research Site
La Plata, Argentina - (and 5 more...)
|
|
| 33 |
NCT03566732 |
Recruiting |
ERANet-LAC CODE: International Care Of the Dying Evaluation |
- Neoplasms
- Bereavement
- Quality of Life
|
|
Observational
|
|
- University of Bergen
- Sue Ryder House administered by Pallmed
- Mutualista Asociación Hospital Evangélico
- (and 4 more...)
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- The proportion of bereaved relatives who perceived that the deceased patient was treated with dignity and respect, by nurses, and by doctors
- The proportion of bereaved relatives who perceived that they themselves were adequately supported in the patient's last days of life
- CODE (Care of the Dying Evaluation questionnaire) support and time of doctors and nurses subscale
- (and 7 more...)
|
700 |
All |
18 Years and older (Adult, Older Adult) |
NCT03566732 |
ELAC2015/T07-0545 |
|
August 15, 2017 |
November 15, 2018 |
November 15, 2018 |
June 25, 2018 |
June 28, 2018 |
|
- Hospital Carlos B. Udaondo
Buenos Aires, Argentina - Instituto de Investigaciones Médicas Alfredo Lanari. Universidad de Buenos Aires
Buenos Aires, Argentina - Hospital Universitario Privado de Córdoba
Córdoba, Argentina - (and 17 more...)
|
|
| 34 |
NCT03020303 |
Recruiting |
Aldosterone bloCkade for Health Improvement EValuation in End-stage Renal Disease |
|
- Drug: Spironolactone 25Mg Tablet
- Drug: Placebo Oral Tablet
|
Interventional
|
Phase 3 |
- Population Health Research Institute
- Canadian Institutes of Health Research (CIHR)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Prevention
|
- Death or hospitalization for heart failure
- Cause specific death
- Hospitalization for heart failure
- (and 3 more...)
|
2750 |
All |
18 Years and older (Adult, Older Adult) |
NCT03020303 |
ACHIEVE |
ACHIEVE |
July 7, 2017 |
April 2023 |
September 2023 |
January 13, 2017 |
November 15, 2018 |
|
- Canberra Hospital
Garran, Australian Capital Territory, Australia - Concord Repatriation General Hospital
Concord, New South Wales, Australia - Sunshine Coast University Hospital
Birtinya, Queensland, Australia - (and 15 more...)
|
|
| 35 |
NCT02884765 |
Recruiting |
Bilateral Condylar Fractures Registry |
- Bilateral Condylar Fracture of the Mandible
|
- Procedure: Non-surgical
- Procedure: Non-surgical / Surgical
- Procedure: Surgical
|
Observational
|
|
- AO Clinical Investigation and Documentation
- AO CMF
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Mandibular movements (mobility index)
|
250 |
All |
18 Years to 90 Years (Adult, Older Adult) |
NCT02884765 |
RP_BCFx_1.0 |
BCFx |
January 2017 |
December 2019 |
May 2020 |
August 31, 2016 |
December 6, 2017 |
|
- University of Kentucky Chandler Medical Center
Lexington, Kentucky, United States - University of Louisville
Louisville, Kentucky, United States - University of Texas Health Science Center at San Antonio
San Antonio, Texas, United States - (and 18 more...)
|
|
| 36 |
NCT02765503 |
Recruiting |
Resource Sparing Curative Radiotherapy for Locally Advanced Squamous Cell Cancer of the Head and Neck: The HYPNO Trial |
- Squamous Cell Carcinoma of the Head and Neck
|
- Radiation: External beam radiotherapy
|
Interventional
|
Phase 3 |
- International Atomic Energy Agency
- Centro de Lucha contra el Cáncer, Montevideo, Uruguay
- Institute Rotary Cancer Hospital, New Delhi, India
- (and 10 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Primary tumor control in T and N position
- Treatment related late Grade 2+ toxicity (CTCAE 4.0)
- Overall survival
- (and 3 more...)
|
836 |
All |
18 Years and older (Adult, Older Adult) |
NCT02765503 |
E33035 |
HYPNO |
March 2014 |
November 2018 |
November 2021 |
May 6, 2016 |
March 30, 2017 |
|
- Fundacion Escuela de Medicina Nuclear
Mendoza, Argentina - Instituto Naciolal de Oncologia y Radiobiologia (INOR)
Havana, Cuba - Department of Radiation Oncology, V.N. Cancer Center, GKNM Hospital
Coimbatore, India - (and 8 more...)
|
|
| 37 |
NCT02570737 |
Enrolling by invitation |
Latin American Pulmonary Hypertension Registry |
|
|
Observational
|
|
- Asociacion Latinoamericana de Torax
- Actelion
- Bayer
- Ferrer Internacional S.A.
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Major adverse cardiovascular events
- Cardiovascular death
|
500 |
All |
Child, Adult, Older Adult |
NCT02570737 |
Cardioneumology |
RELAHP |
April 2014 |
July 2018 |
April 2019 |
October 7, 2015 |
January 24, 2017 |
|
- Hospital Universitario, Fundación Favaloro
Buenos Aires, Argentina - Hospital Clementino Fraga - Universidade Federal do Rio de Janeiro
Rio de Janeiro, Brazil - Instituto Nacional del Tórax, Universidad de Chile
Santiago, Chile - (and 5 more...)
|
|
| 38 |
NCT02563054 |
Completed |
A Study of Capecitabine (Xeloda) in Participants With Advanced or Metastatic Gastric Cancer |
|
- Drug: 5-Fluorouracil
- Drug: Capecitabine
- Drug: Cisplatin
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Time to disease progression
- Objective tumor response rate
- Overall survival
- (and 3 more...)
|
316 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT02563054 |
ML17032 |
|
April 2003 |
August 2010 |
August 2010 |
September 29, 2015 |
November 2, 2016 |
|
- Buenos Aires, Argentina
- Buenos Aires, Argentina
- Rosario, Argentina
- (and 42 more...)
|
|
| 39 |
NCT01966471 |
Active, not recruiting |
A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer |
|
- Drug: Trastuzumab Emtansine
- Drug: Trastuzumab
- Drug: Pertuzumab
- (and 6 more...)
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Invasive Disease-Free Survival (IDFS) in the Overall Population
- IDFS in the Node-Positive Subpopulation
- IDFS Plus Second Primary Non-Breast Cancer
- (and 8 more...)
|
1846 |
All |
18 Years and older (Adult, Older Adult) |
NCT01966471 |
BO28407
2012-004902-82 |
|
January 31, 2014 |
January 31, 2024 |
January 31, 2024 |
October 21, 2013 |
September 24, 2018 |
|
- Ironwood Cancer TX & Rsch Ctrs
Chandler, Arizona, United States - HonorHealth Research Institute - Pima Center
Scottsdale, Arizona, United States - Kaiser Permanente - Oakland
Oakland, California, United States - (and 338 more...)
|
|
| 40 |
NCT01881659 |
Recruiting |
Cervical Cancer Screening With Human Papillomavirus Testing |
|
|
Observational
|
|
- International Agency for Research on Cancer
|
Other |
- Observational Model: Other
- Time Perspective: Prospective
|
- Number of participants with histologically confirmed cervical intraepithelial neoplasia grade 3 or cancer (CIN3+), including CIN2 positive for p16, on reviewed histology
- Number of participants with histologically confirmed CIN2, CIN3 or cancer (CIN2+) on reviewed histology
|
50000 |
Female |
30 Years to 64 Years (Adult) |
NCT01881659 |
IEC 12-27 |
ESTAMPA |
June 2013 |
December 2019 |
December 2019 |
June 19, 2013 |
June 8, 2018 |
|
- Hopsital de Clinicas
Buenos Aires, Argentina - Insituto Malbran - Hospital Posadas
Buenos Aires, Argentina - Universidad San Francisco Xavier de Chuquisaca
Sucre, Bolivia - (and 10 more...)
|
|
| 41 |
NCT01800006 |
Completed |
Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation in Latinamerica and EMEA Region |
|
- Drug: Rivaroxaban (Xarelto, BAY59-7939)
|
Observational
|
|
- Bayer
- Janssen Research & Development, LLC
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Adjudicated major bleeding events
- Safety variables will be summarized using descriptivestatistics based on adverse events collection
- All cause mortality
- (and 8 more...)
|
2101 |
All |
18 Years and older (Adult, Older Adult) |
NCT01800006 |
16691
XA1206 |
XANTUS-EL |
January 14, 2013 |
January 16, 2016 |
June 20, 2016 |
February 27, 2013 |
June 21, 2017 |
|
- Many Locations, Argentina
- Many Locations, Azerbaijan
- Many Locations, Bahrain
- (and 14 more...)
|
|
| 42 |
NCT01650064 |
Completed |
Latin America Hip Fracture Mortality Study |
|
|
Observational
|
|
- AO Clinical Investigation and Documentation
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Death
- Harris Hip Score
- Parker Mobility Score
- (and 4 more...)
|
168 |
All |
60 Years to 110 Years (Adult, Older Adult) |
NCT01650064 |
LAMOS |
LAMOS |
January 2013 |
April 2016 |
December 2016 |
July 26, 2012 |
January 24, 2017 |
|
- Hospital Italiano de Buenos Aires
Buenos Aires, Argentina - Hospital Vila Velha
Espirito Santo, Brazil - IOT - Instituto de Ortopedia de Traumatologia de Passo Fundo
Passo Fundo, Brazil - (and 13 more...)
|
|
| 43 |
NCT01643707 |
Active, not recruiting |
Registry to Improve the Adoption of Consensus Treatment Guidelines (IMPROVE Brady) |
|
- Behavioral: Evidence based guidelines and tools
|
Observational
|
|
- Medtronic Cardiac Rhythm and Heart Failure
|
Industry |
- Observational Model: Other
- Time Perspective: Prospective
|
- The absolute change in the proportion of subjects diagnosed with SND before and after intervention
- The absolute change in the proportion of subjects receiving indicated therapy before and after intervention
- The proportion of Phase I subjects diagnosed with SND and the number of diagnoses that result in indicated therapy
- (and 4 more...)
|
1346 |
All |
18 Years and older (Adult, Older Adult) |
NCT01643707 |
IMPROVE Brady |
IMPROVE Brady |
July 2012 |
November 2020 |
November 2020 |
July 18, 2012 |
October 19, 2018 |
|
- Hospital General de Agudos
Buenos Aires, Argentina - National Heart Foundation Hospital and Research Institute
Dhaka, Bangladesh - United Hospital Limited
Dhaka, Bangladesh - (and 18 more...)
|
|
| 44 |
NCT01493544 |
Completed |
Prevalence Study and Regular Practice Among General Practitioners in Populations at Risk of Chronic Obstructive Pulmonary Disease (COPD) in Latin America |
- Chronic Obstructive Pulmonary Disease
|
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Cross-Sectional
|
- Number of participants with an affirmative response to specific categories on the PUMA questionnaire.
- FEV1 spirometry measures.
- SaO2 (Arterial Oxygen Saturation) - pulse oximetry.
- (and 3 more...)
|
1907 |
All |
40 Years and older (Adult, Older Adult) |
NCT01493544 |
NIS-RLA-XXX-2011/1 |
PUMA PROJECT |
February 2012 |
October 2012 |
October 2012 |
December 16, 2011 |
April 26, 2013 |
|
- Research Site
Escobar, Buenos Aires, Argentina - Research Site
Ezeiza, Buenos Aires, Argentina - Research Site
Los Polvorines, Buenos Aires, Argentina - (and 15 more...)
|
|
| 45 |
NCT01297504 |
Completed
Has Results |
A One-Year Observation of Palivizumab in Infants at Risk for Respiratory Syncytial Virus Infection in Latin America |
- Respiratory Syncytial Virus Infection
|
|
Observational
|
|
- AbbVie (prior sponsor, Abbott)
- Fundasamin (Argentina)
- AbbVie
|
Industry / Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Characterization of Participants With Risk Factors for Respiratory Syncytial Virus (RSV) Infection
- Distribution of Comorbidities in Study Participants
- Number of Participants With Hospitalizations for Lower Respiratory Tract Infection and RSV
- (and 4 more...)
|
464 |
All |
up to 2 Years (Child) |
NCT01297504 |
P10-129 |
|
February 2011 |
August 2013 |
August 2013 |
February 16, 2011 |
October 1, 2014 |
September 3, 2014 |
- Site Reference ID/Investigator# 52185
Buenos Aires, Argentina - Site Reference ID/Investigator# 52182
Buenos Aires, Argentina - Site Reference ID/Investigator# 52183
Buenos Aires, Argentina - (and 21 more...)
|
|
| 46 |
NCT01239732 |
Completed
Has Results |
A Study of the Addition of Avastin (Bevacizumab) to Carboplatin and Paclitaxel Therapy in Patients With Ovarian Cancer |
|
- Drug: Paclitaxel
- Drug: Bevacizumab
- Drug: Carboplatin
|
Interventional
|
Phase 3 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percentage of Participants With at Least One Adverse Event (AE)
- Progression-Free Survival (PFS)
- Percentage of Participants Achieving Best Overall Response of Complete Response (CR) or Partial Response (PR) According to RECIST Version 1.0
- (and 5 more...)
|
1021 |
Female |
18 Years and older (Adult, Older Adult) |
NCT01239732 |
MO22923
2010-019525-34 |
|
December 2010 |
March 2015 |
March 2015 |
November 11, 2010 |
June 10, 2016 |
June 10, 2016 |
- Buenos Aires, Argentina
- Buenos Aires, Argentina
- Buenos Aires, Argentina
- (and 239 more...)
|
|
| 47 |
NCT01194570 |
Active, not recruiting
Has Results |
A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis |
- Multiple Sclerosis, Primary Progressive
|
- Drug: Ocrelizumab
- Other: Placebo
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Time to Onset of Clinical Disability Progression (CDP) Sustained for at Least 12 Weeks During the Double-Blind Treatment Period
- Time to Onset of Clinical Disability Progression (CDP) Sustained for at Least 24 Weeks During the Double-Blind Treatment Period
- Percent Change From Baseline in Timed 25-Foot Walk (T25-FW) at Week 120
- (and 4 more...)
|
732 |
All |
18 Years to 55 Years (Adult) |
NCT01194570 |
WA25046
2010-020338-25 |
|
March 2, 2011 |
July 23, 2015 |
December 9, 2021 |
September 3, 2010 |
September 27, 2018 |
December 26, 2017 |
- Phoenix Neurological Associates Ltd
Phoenix, Arizona, United States - Barrow Neurology Clinic
Phoenix, Arizona, United States - Hope Research Institute
Phoenix, Arizona, United States - (and 216 more...)
|
|
| 48 |
NCT01142674 |
Recruiting |
T-Cell Project: Prospective Collection of Data in Patients With Peripheral T-Cell Lymphoma |
- Lymphoma, T-Cell, Peripheral
|
|
Observational
|
|
- Associazione Angela Serra per la ricerca sul cancro
- Fondazione Italiana Linfomi ONLUS
- International Peripheral T-Cell Lymphoma Project (Study group)
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Overall Survival (OS)
- Event Free Survival (EFS)
- Remission rate with initial therapy
- Progression Free Survival (PFS)
|
2000 |
All |
18 Years and older (Adult, Older Adult) |
NCT01142674 |
T-Cell Project |
|
September 2006 |
December 2017 |
December 2022 |
June 11, 2010 |
August 9, 2016 |
|
- Stanford University Medical Center
Palo Alto, California, United States - Yale Cancer Center
New Haven, Connecticut, United States - St Louis Washington University
St Louis, Missouri, United States - (and 73 more...)
|
|
| 49 |
NCT00949910 |
Completed
Has Results |
An Expanded Access Program of Tarceva (Erlotinib) in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) |
- Non-Small Cell Lung Cancer
|
|
Interventional
|
Phase 4 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percentage of Participants With Objective Response According to Response Evaluation Criteria in Solid Tumors (RECIST)
- Percentage of Participants With Disease Control According to RECIST
- Percentage of Participants by Best Overall Response According to RECIST
- (and 4 more...)
|
6586 |
All |
18 Years and older (Adult, Older Adult) |
NCT00949910 |
MO18109
2004-000564-28
INC-9042 |
|
November 2004 |
April 2009 |
April 2009 |
July 31, 2009 |
October 5, 2016 |
October 4, 2016 |
- Tirana, Albania
- Buenos Aires, Argentina
- Buenos Aires, Argentina
- (and 541 more...)
|
|
| 50 |
NCT00812175 |
Completed |
Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of Its Treatment With Sorafenib |
- Carcinoma, Hepatocellular
|
- Drug: Sorafenib (Nexavar, BAY43-9006)
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- The safety of Nexavar in all patients with unresectable HCC who are candidates for systemic therapy and in whom a decision to treat with Nexavar has been made under real-life practice conditions
- Efficacy [overall survival (OS), progression-free survival (PFS), time to progression (TTP), response rate (RR), stable disease(SD) rate] by the Response Evaluation Criteria in Solid Tumor (RECIST) Criteria of Nexavar
- The duration of therapy with Nexavar in a variety of settings according to patient characteristics and other variables
- (and 4 more...)
|
3371 |
All |
18 Years and older (Adult, Older Adult) |
NCT00812175 |
13414
NX0802 |
GIDEON |
January 2009 |
April 2012 |
April 2012 |
December 22, 2008 |
October 17, 2016 |
|
- Many Locations, Alabama, United States
- Many Locations, Arizona, United States
- Many Locations, Arkansas, United States
- (and 72 more...)
|
|
| 51 |
NCT00754572 |
Completed
Has Results |
A Study to Assess the Effect of Tocilizumab Plus Methotrexate on Safety and Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis |
|
- Drug: tocilizumab [RoActemra/Actemra]
- Drug: methotrexate
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percentage of Participants With American College of Rheumatology (ACR) 50 Response at Week 24
- Percentage of Participants With ACR20 and ACR70 Response at Week 24
- Time to Onset of ACR20, ACR50, and ACR70
- (and 21 more...)
|
418 |
All |
18 Years and older (Adult, Older Adult) |
NCT00754572 |
ML21530 |
|
February 2009 |
October 2012 |
October 2012 |
September 18, 2008 |
May 15, 2015 |
May 15, 2015 |
- Buenos Aires, Argentina
- Buenos Aires, Argentina
- Buenos Aires, Argentina
- (and 67 more...)
|
|
| 52 |
NCT00688740 |
Completed
Has Results |
Docetaxel in Node Positive Adjuvant Breast Cancer |
|
- Drug: Docetaxel
- Drug: 5-fluorouracil
- Drug: Doxorubicin
- Drug: Cyclophosphamide
|
Interventional
|
Phase 3 |
- Sanofi
- Cancer International Research Group (CIRG)
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants With Disease-Free Survival Events
- Number of Participants With Overall Survival Events
- Number of Participants With Second Primary Malignancies (Toxicity)
|
1491 |
Female |
18 Years to 70 Years (Adult, Older Adult) |
NCT00688740 |
EFC6041
XRP6976D-316
BCIRG001 |
TAX316 |
June 1997 |
January 2010 |
January 2010 |
June 3, 2008 |
February 16, 2011 |
February 14, 2011 |
- Sanofi-Aventis Administrative Office
Bridgewater, New Jersey, United States - Sanofi-Aventis Administrative Office
Buenos Aires, Argentina - Sanofi-Aventis Administrative Office
Wien, Austria - (and 17 more...)
|
|
| 53 |
NCT00502996 |
Completed
Has Results |
A Non-Comparative Study to Assess the Safety of MabThera (Rituximab) in Patients With Rheumatoid Arthritis. |
|
- Drug: Methotrexate
- Drug: rituximab [MabThera/Rituxan]
|
Interventional
|
Phase 3 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants With Any Adverse Event, Any Serious Adverse Event, and Death
- Number of Participants With AEs According to Degree of Intensity
- Number of Participants With AEs Leading to Discontinuation and Any Drug Related AEs and SAEs
- (and 18 more...)
|
246 |
All |
18 Years and older (Adult, Older Adult) |
NCT00502996 |
ML19385 |
|
February 2006 |
December 2008 |
December 2008 |
July 18, 2007 |
October 14, 2016 |
October 14, 2016 |
- Buenos Aires, Argentina
- Buenos Aires, Argentina
- Buenos Aires, Argentina
- (and 47 more...)
|
|
| 54 |
NCT00485979 |
Completed |
Treatment of Larotaxel/Docetaxel, +/- Trastuzumab, After Anthracycline-cyclophosphamide in Breast Cancer Patients |
|
- Drug: larotaxel (XRP9881)
- Drug: docetaxel
- Drug: trastuzumab
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Pathological response will be assessed according to Chevallier criteria for patients who underwent surgery.
- Clinical Response Rate, Rate of breast conservation, Progression-Free Survival, Overall Survival, pathological response according to NSABP and Sataloff criteria for patients who underwent surgery
- Safety and tolerability profile
|
330 |
Female |
18 Years to 75 Years (Adult, Older Adult) |
NCT00485979 |
EFC10073
EudraCT 2006-006473-24 |
SATIN |
June 2007 |
August 2010 |
August 2010 |
June 13, 2007 |
June 28, 2011 |
|
- Sanofi-Aventis Administrative Office
Diegem, Belgium - Sanofi-Aventis Administrative Office
Sao Paulo, Brazil - Sanofi-Aventis Administrative Office
Paris, France - (and 5 more...)
|
|
| 55 |
NCT00408278 |
Completed |
Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia (PETHEMA LPA 2005) |
- Acute Promyelocytic Leukemia
|
- Drug: ATRA
- Drug: Idarubicina
- Drug: Mitoxantrone
- Drug: ARA-C
|
Interventional
|
Phase 4 |
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To evaluate the efficacy and toxicity of a risk-adapted protocol that use idarubicin for induction and consolidation therapy in patients with APL.
- To evaluate the impact of mitoxantrone reduction on the event-free, disease-free, and overall survival.
- To evaluate the impact of the addition of ara-C to idarubicin courses of consolidation for high-risk patients on the event-free, disease-free, and overall survival
- (and 2 more...)
|
300 |
All |
up to 75 Years (Child, Adult, Older Adult) |
NCT00408278 |
LPA 2005 |
|
July 2005 |
April 2012 |
December 2013 |
December 6, 2006 |
October 28, 2014 |
|
- PALG
Lodz, Poland - Hospital General
Albacete, Spain - Hospital general
Alicante, Spain - (and 39 more...)
|
|
| 56 |
NCT00401323 |
Completed |
Taxotere (Docetaxel) in 1st Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma |
- Head and Neck Neoplasms
- Neoplasm Recurrence, Local
- Neoplasm Metastasis
|
- Drug: docetaxel (XRP6976)
- Drug: cisplatin
- Drug: 5-fluorouracil (5-FU)
|
Interventional
|
Phase 2
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- time to progression
- overall survival, overall response rate (complete response + partial response), duration of response, and time to treatment failure
|
568 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT00401323 |
EFC6051
XRP6976G-322 |
|
January 1998 |
June 2003 |
June 2003 |
November 20, 2006 |
January 20, 2011 |
|
- sanofi-aventis US
Bridgewater, New Jersey, United States - Sanofi-Aventis
Buenos Aires, Argentina - sanofi-aventis, Australia
Macquarie Park, New South Wales, Australia - (and 17 more...)
|
|
| 57 |
NCT00377169 |
Completed |
Collection of Blood Samples From SMART Study Participants for Future Genetic Studies |
|
|
Observational
|
|
- National Institute of Allergy and Infectious Diseases (NIAID)
- Community Programs for Clinical Research on AIDS
|
NIH / Other |
|
|
3261 |
All |
13 Years and older (Child, Adult, Older Adult) |
NCT00377169 |
CPCRA 065H
SMART |
|
|
January 2006 |
January 2006 |
September 15, 2006 |
November 1, 2016 |
|
- AltaMed Health Services Corporation
Los Angeles, California, United States - Los Angeles Gay & Lesbian Community Service Center
Los Angeles, California, United States - VA Greater Los Angeles Healthcare System
Los Angeles, California, United States - (and 39 more...)
|
|
| 58 |
NCT00368680 |
Unknown † |
Early CPAP in Respiratory Distress Syndrome |
- Respiratory Distress Syndrome
|
- Device: Early Bubble CPAP
|
Interventional
|
Phase 4 |
- Pontificia Universidad Catolica de Chile
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Need for mechanical ventilation
- Days of oxygen therapy
- Days of mechanical ventilation
- (and 6 more...)
|
256 |
All |
up to 30 Minutes (Child) |
NCT00368680 |
NEO032006 |
|
January 2007 |
April 2008 |
September 2009 |
August 25, 2006 |
December 24, 2010 |
|
- Servicio de Neonatología, Hospital de Clínicas José de San Martín
Buenos Aires, Argentina - Servicio de Neonatología, Hospital Fernández
Buenos Aires, Argentina - Servicio de Neonatología, Hospital Italiano
Buenos Aires, Argentina - (and 11 more...)
|
|
| 59 |
NCT00312208 |
Completed
Has Results |
Docetaxel in Breast Cancer |
|
- Drug: docetaxel, doxorubicin, cyclophosphamide
- Drug: Docetaxel,doxorubicin, cyclophosphamide
|
Interventional
|
Phase 3 |
- Sanofi
- Cancer International Research Group (CIRG)
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Local, Regional or Metastatic Relapse, or Second Primary Cancer, or Death From Any Cause (Disease-Free Survival)
- Death From Any Cause (Overall Survival)
|
3299 |
Female |
18 Years to 70 Years (Adult, Older Adult) |
NCT00312208 |
TAX_GMA_301
BCIRG 005 |
|
November 2001 |
October 2008 |
October 2013 |
April 7, 2006 |
December 30, 2013 |
February 17, 2010 |
- Sanofi-Aventis
Bridgewater, New Jersey, United States - Sanofi-Aventis
Buenos Aires, Argentina - Sanofi-Aventis
Macquarie Park, Australia - (and 34 more...)
|
|
| 60 |
NCT00262067 |
Unknown †
Has Results |
A Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy in Untreated Metastatic Breast Cancer (RIBBON 1) |
|
- Drug: Bevacizumab
- Drug: Placebo
- Drug: Chemotherapy
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Progression-free Survival (PFS) as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST)
- Objective Response as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST)
- Duration of Objective Response as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST)
- (and 3 more...)
|
1237 |
All |
18 Years and older (Adult, Older Adult) |
NCT00262067 |
AVF3694g
BO20094 |
|
December 2005 |
July 2008 |
December 2013 |
December 6, 2005 |
December 13, 2013 |
October 25, 2013 |
- Fullerton, California, United States
- Santa Barbara, California, United States
- Iowa City, Iowa, United States
- (and 89 more...)
|
|
| 61 |
NCT00239681 |
Terminated
Has Results |
JUPITER - Crestor 20mg Versus Placebo in Prevention of Cardiovascular (CV) Events |
- Elevated High-sensitivity C-Reactive Protein (hsCRP)
|
- Drug: Rosuvastatin
- Other: Placebo
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Time to Major Cardiac Event (Cardiovascular Death, Stroke, Myocardial Infarction, Hospitalization Due to Unstable Angina or Arterial Revascularization)
- Time to Death Due to Any Cause
- Time to Non-cardiovascular Death
- (and 3 more...)
|
17802 |
All |
50 Years and older (Adult, Older Adult) |
NCT00239681 |
D3560L00030
Jupiter
4522US/0011 |
|
February 2003 |
September 2008 |
September 2008 |
October 17, 2005 |
March 24, 2014 |
March 24, 2014 |
- Research Site
Birmingham, Alabama, United States - Research Site
Calera, Alabama, United States - Research Site
Columbiana, Alabama, United States - (and 856 more...)
|
|
| 62 |
NCT00097786 |
Completed
Has Results |
Long-term Study of Nateglinide+Valsartan to Prevent or Delay Type II Diabetes Mellitus and Cardiovascular Complications |
- Diabetes Mellitus, Type 2
|
- Drug: Valsartan 160 mg + nateglinide 60 mg
- Drug: Valsartan 160 mg + nateglinide placebo
- Drug: Nateglinide 60 mg + valsartan placebo
- Drug: Valsartan placebo + nateglinide placebo
|
Interventional
|
Phase 3 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Allocation: Randomized
- Intervention Model: Factorial Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Prevention
|
- Percentage of Patients Reaching the Endpoint: Progression to Diabetes - Valsartan Versus Non-valsartan
- Percentage of Patients Reaching the Endpoint: Extended Morbidity and Mortality Event - Valsartan Versus Non-valsartan
- Percentage of Patients Reaching the Endpoint: Core Cardiovascular Morbidity and Mortality Event - Valsartan Versus Non-valsartan
- (and 3 more...)
|
9306 |
All |
50 Years and older (Adult, Older Adult) |
NCT00097786 |
CDJN608B2302 |
Navigator |
January 2002 |
October 2009 |
October 2009 |
December 1, 2004 |
June 29, 2011 |
May 24, 2011 |
- Investigative Site, New Jersey, United States
- Investigative Site, Argentina
- Investigative Site, Australia
- (and 35 more...)
|
|
| 63 |
NCT00077792 |
Completed |
Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment Thrombolysis in Myocardial Infarction - Study 25 (ExTRACT-TIMI25) |
- Myocardial Infarction
- Acute ST-Segment Elevation
|
- Drug: Enoxaparin sodium (XRP4563)
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Prevention
|
- Composite of all-cause mortality and non-fatal myocardial re-infarction
- Composite of all-cause mortality, non-fatal myocardial re-infarction, and myocardial ischemia leading to urgent revascularization and non-fatal disabling stroke
|
20506 |
All |
18 Years and older (Adult, Older Adult) |
NCT00077792 |
EFC6147
XRP4563B/3001 |
|
October 2002 |
December 2006 |
December 2006 |
February 16, 2004 |
April 20, 2009 |
|
- Sanofi-Aventis Administrative Office
Bridgewater, New Jersey, United States - sanofi-aventis administrative Office
Buenos Aires, Argentina - sanofi-aventis Australia & New Zealand administrative office
Macquarie Park, Australia - (and 45 more...)
|
|
| 64 |
NCT00021255 |
Completed
Has Results |
Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer |
|
- Drug: Doxorubicin
- Drug: Cyclophosphamide
- Drug: Docetaxel
- (and 2 more...)
|
Interventional
|
Phase 3 |
- Sanofi
- Cancer International Research Group (CIRG)
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percentage of Participants With Disease Free Survival at 5 Years
- Percentage of Participants With Disease Free Survival at 10 Years
- Overall Survival- Percentage of Participants Who Survived at 10 Years
|
3222 |
Female |
18 Years to 70 Years (Adult, Older Adult) |
NCT00021255 |
TAX_GMA_302
BCIRG 006 |
|
April 2001 |
December 2014 |
December 2014 |
January 27, 2003 |
November 15, 2016 |
November 15, 2016 |
- Sanofi-Aventis Administrative Office
Bridgewater, New Jersey, United States - Sanofi-Aventis Administrative Office
Buenos Aires, Argentina - Sanofi-Aventis Administrative Office
Macquarie Park, Australia - (and 39 more...)
|
|
Create an RSS feed from your search for:
Download the search results for: